Leaflet RAPTIVA 100mg / ml powder and solvent for solution for injection
Indicated for: psoriasis
Route of administration: injectable
Substance: efalizumab (monoclonal antibody)
ATC: L04AA21 (Antineoplastic and immunomodulating agents | Immunosuppressants | Selective immunosuppressants)
Risk of severe allergic reaction. Seek urgent medical help if serious symptoms occur.
This medicine is subject to additional monitoring.
Use during breastfeeding only on medical advice.
Use during pregnancy only on medical advice.
Efalizumab was a medication previously used for the treatment of chronic plaque psoriasis. It is a monoclonal antibody that works by inhibiting the activation and migration of T-lymphocytes, reducing inflammation and psoriasis symptoms.
The medication was administered as a subcutaneous injection, usually once a week, according to the doctor's instructions. It was effective in alleviating symptoms and improving skin appearance.
Side effects included headache, chills, nausea, and, in rare cases, severe reactions such as progressive multifocal leukoencephalopathy (PML). Its use has been discontinued in many countries due to associated risks.
Consult your doctor to discuss available alternatives for psoriasis treatment. Follow all medical recommendations to ensure the best possible care.
General data about RAPTIVA 100mg / ml
- Substance: efalizumab
- Date of latest medicines list: 01-07-2013
- Product code: W41844002
- Concentration: 100mg / ml
- Pharmaceutical form: powder and solvent for solution for injection
- Quantity: 4
- Product type: Original
- Prescription status: P-RF - Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.